Investigating the effects of Cushing's syndrome on fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to explore the relationship between Cushing's syndrome and the development of Non-Alcoholic Fatty Liver Disease (NAFLD). It will involve patients over 18 years old who are actively diagnosed with Cushing's syndrome. The study will utilize hepatic MRI to assess liver conditions and the prevalence of hepatic steatosis in this patient population. The findings could provide insights into the metabolic complications associated with prolonged cortisol exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Active Cushing's syndrome

Exclusion Criteria:

* Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol)
* Contraindication to MRI

Where it's running

• University Hospital, Angers
  Angers, France Recruiting
• University Hospital, Bordeaux
  Bordeaux, France Recruiting
• University Hospital, Brest
  Brest, France Recruiting
• University Hospital, Grenoble
  Grenoble, France Recruiting
• University Hospital, Lille
  Lille, France Recruiting
• University Hospital, Nantes
  Nantes, France Recruiting

Study contacts

• Principal investigator: Claire BRIET — University Hospital of Anger
• Study coordinator: Claire BRIET
• Email: claire.briet@chu-angers.fr
• Phone: 02 41 35 36 37

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Myokines in metabolic and endocrine diseases linked to sarcopenia

  This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe · NCT07703683

• Osilodrostat for high blood pressure caused by Cushing's syndrome

  This study tests whether osilodrostat can lower high blood pressure in adults with Cushing's syndrome-related hypercortisolemia.

  Recruiting at 3 sites Phase 4 Recordati Group · Jacksonville, Florida and 2 other locations · NCT07247162

• Normal ranges and diagnostic cut-offs for salivary cortisol

  This project will test two saliva cortisol methods — a lab LC‑MS assay and a rapid fluorescence immunoassay — to find normal ranges and the best diagnostic cut-offs for adults with suspected Cushing syndrome or adrenal insufficiency.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07168122

• Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver

  This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.

  Recruiting Phenomen Pharma · Tyumen, Tyumen Oblast · NCT07068191

• Using modified Desmopressin for better imaging in Cushing syndrome

  This study is testing a new way to use a modified form of Desmopressin to improve imaging for people with Cushing syndrome, helping doctors better see and understand pituitary tumors before surgery.

  Recruiting Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh · NCT06962202

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.